LifeVantage (LFVN) Registration Filing summary

Company overview and business model

• Focuses on nutrigenomics, offering scientifically validated dietary supplements, weight management, pre- and probiotics, nootropics, and skin/hair care products through a direct sales model in multiple international markets.

• Provides a commission-based direct sales opportunity to independent consultants, with products sold in the US and over a dozen other countries.

• Product portfolio includes flagship Protandim®, LifeVantage® supplements, TrueScience® skin/hair care, Petandim® for pets, AXIO® nootropic drinks, and LoveBiome® gut health supplements.

Financial performance and metrics

• As of March 4, 2026, 12,804,772 shares of common stock were outstanding, held by 77 record holders.

• Aggregate market value of common stock held by non-affiliates was $65,580,155 based on 10,343,873 shares as of February 26, 2026.

• No securities were sold under the referenced registration instruction in the prior twelve months.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, capital expenditures, corporate expenses, and potential acquisitions, with no current commitments for acquisitions.

• Management retains broad discretion over allocation of proceeds, with interim investment in short-term, investment-grade, interest-bearing instruments.